Habibe Hezer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Habibe Hezer has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Hatice Kilic
Ankara Yıldırım Beyazıt University, School of Medicine, Department of Pulmonary Diseases. Ankara, Türkiye
10 shared publications - Emine Argüder
Faculty of Medicine Department of Chest Diseases Ankara Yıldırım Beyazıt University Ankara Türkiye
7 shared publications - Hatice Canan Hasanoğlu
Department of Pulmonary Diseases, Ankara Yıldırım Beyazıt University Faculty of Medicine, Ankara, Türkiye
7 shared publications - Aysegul Karalezli
Faculty of Medicine, Ankara Yildirim Beyazit University, 06800 Ankara, Turkey
6 shared publications - Ebru Şengül Parlak
Department of Chest Diseases Ankara Bilkent City Hospital Ankara Türkiye
6 shared publications - Adalet Aypak
Department of Infectious Disease and Clinical Microbiology, Ankara Bilkent City Hospital, University of Health Sciences
3 shared publications
Latest Publications
- Open Access
The Association Between the STOP-Bang Score and the Integrated Pulmonary Index in Patients Undergoing Endobronchial Ultrasound with Sedation: The STOP OSA-IPI Cohort Study
Background and Perspectives: Obstructive sleep apnea (OSA) is a prevalent condition associated with increased perioperative risks. Endobronchial ultrasound (EBUS), a diagnostic and staging procedure requiring deep sedation, may pose additional risks for patients at high risk of OSA. The Integrated Pulmonary Index (IPI), derived from capnography and vital signs, offers a single numerical value reflecting respiratory status. This study aimed to assess the association between high OSA risk and adverse events using the IPI during EBUS under sedation. Materials and Methods: This prospective cohort study included 65 patients undergoing EBUS with sedation between December 2024 and April 2025 at a tertiary referral center. STOP-Bang questionnaire scores were used to stratify patients into high- (≥3) and low-risk (Results: Forty-three patients (66.2%) were classified as high risk for OSA. Patients with high STOP-Bang scores were older and had higher BMI, comorbidity rates, and ASA scores (all p < 0.05). IPI values were lowest between 5 and 10 min, accompanied by more frequent interventions. Logistic regression showed no significant association between STOP-Bang scores and low IPI or hypoxemia. GLMM analysis also indicated no significant association between high OSA risk and low IPI (OR = 1.02; 95% CI = 0.36–2.86; p = 0.974). Hypoxemia was nearly threefold higher in high-risk patients, though not statistically significant (p = 0.080). Conclusions: Although no statistically significant association was identified between high OSA risk and adverse respiratory events, GLMM analyses revealed that patients with high STOP-Bang scores demonstrated approximately three times higher odds of developing hypoxemia (OR = 2.76; 95% CI = 0.99–7.66; p = 0.052), a result that approached statistical significance. The present findings do not support the routine use of IPI-based monitoring in this setting, and further adequately powered studies are warranted. The early procedural period (5–10 min) is critical for hypoxemia and respiratory compromise.
Open AccessThe Association Between the STOP-Bang Score and the Integrated Pulmonary Index in Patients Undergoing Endobronchial Ultrasound with Sedation: The STOP OSA-IPI Cohort Study
Background and Perspectives: Obstructive sleep apnea (OSA) is a prevalent condition associated with increased perioperative risks. Endobronchial ultrasound (EBUS), a diagnostic and staging procedure requiring deep sedation, may pose additional risks for patients at high risk of OSA. The Integrated Pulmonary Index (IPI), derived from capnography and vital signs, offers a single numerical value reflecting respiratory status. This study aimed to assess the association between high OSA risk and adverse events using the IPI during EBUS under sedation. Materials and Methods: This prospective cohort study included 65 patients undergoing EBUS with sedation between December 2024 and April 2025 at a tertiary referral center. STOP-Bang questionnaire scores were used to stratify patients into high- (≥3) and low-risk (Results: Forty-three patients (66.2%) were classified as high risk for OSA. Patients with high STOP-Bang scores were older and had higher BMI, comorbidity rates, and ASA scores (all p < 0.05). IPI values were lowest between 5 and 10 min, accompanied by more frequent interventions. Logistic regression showed no significant association between STOP-Bang scores and low IPI or hypoxemia. GLMM analysis also indicated no significant association between high OSA risk and low IPI (OR = 1.02; 95% CI = 0.36–2.86; p = 0.974). Hypoxemia was nearly threefold higher in high-risk patients, though not statistically significant (p = 0.080). Conclusions: Although no statistically significant association was identified between high OSA risk and adverse respiratory events, GLMM analyses revealed that patients with high STOP-Bang scores demonstrated approximately three times higher odds of developing hypoxemia (OR = 2.76; 95% CI = 0.99–7.66; p = 0.052), a result that approached statistical significance. The present findings do not support the routine use of IPI-based monitoring in this setting, and further adequately powered studies are warranted. The early procedural period (5–10 min) is critical for hypoxemia and respiratory compromise.
- Open Access
- 15 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (10) , 1509
Associated Factors for Non-Diagnostic Cytopathology in the Endobronchial Ultrasound-Transbronchial Needle Aspiration: A Retrospective Cohort Study
Introduction: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is widely used for diagnosing pulmonary diseases causing mediastinal lymphadenopathy. However, non-diagnostic results may occur. This study investigated factors associated with non-diagnostic cytological results in EBUS-TBNA. Methods: This retrospective study included patients who underwent EBUS-TBNA at a tertiary hospital between March 2019 and December 2023. Data on demographics, biopsy techniques, cyto-/histopathological results, sonographic lymph node measurements, and pre-procedural PET-CT SUVmax values were recorded. Cytological results were classified as diagnostic or non-diagnostic. We analyzed the characteristics and associated factors of patients who were non-diagnostically identified. Results: Among 776 patients undergoing EBUS-TBNA, 502 (64.7%) were male, with a mean age of 61.5 ± 12.6 years. A total of 1110 lymph nodes were sampled. Of the patients, 14.1% had a non-diagnostic cytology. Among the diagnosed patients, cytological findings showed 58.9% non-malignant, 41.1% malignant. The most sampled station was station 7 (72.9%), with an average of 5.9 ± 1.4 aspirations. Diagnostic cases had significantly more aspirations (p = 0.022) and sampled larger lymph node sizes (p < 0.001). Each 1 mm increase in lymph node size raised the likelihood of diagnostic results by 1.04 times (adjOR = 1.04, 95% CI = 1.02–1.08, p = 0.002). The largest lymph node size significantly predicted diagnostic results (AUROC = 0.611, p < 0.001). A cut-off of 19.55 mm had 67.0% sensitivity and 52.2% specificity. Conclusions: Sampled larger lymph nodes increase diagnostic yield in EBUS-TBNA, reducing the need for repeat procedures and enabling earlier treatment, thereby decreasing morbidity and mortality.
- 15 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (10) , 1509
Open AccessAssociated Factors for Non-Diagnostic Cytopathology in the Endobronchial Ultrasound-Transbronchial Needle Aspiration: A Retrospective Cohort Study
Introduction: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is widely used for diagnosing pulmonary diseases causing mediastinal lymphadenopathy. However, non-diagnostic results may occur. This study investigated factors associated with non-diagnostic cytological results in EBUS-TBNA. Methods: This retrospective study included patients who underwent EBUS-TBNA at a tertiary hospital between March 2019 and December 2023. Data on demographics, biopsy techniques, cyto-/histopathological results, sonographic lymph node measurements, and pre-procedural PET-CT SUVmax values were recorded. Cytological results were classified as diagnostic or non-diagnostic. We analyzed the characteristics and associated factors of patients who were non-diagnostically identified. Results: Among 776 patients undergoing EBUS-TBNA, 502 (64.7%) were male, with a mean age of 61.5 ± 12.6 years. A total of 1110 lymph nodes were sampled. Of the patients, 14.1% had a non-diagnostic cytology. Among the diagnosed patients, cytological findings showed 58.9% non-malignant, 41.1% malignant. The most sampled station was station 7 (72.9%), with an average of 5.9 ± 1.4 aspirations. Diagnostic cases had significantly more aspirations (p = 0.022) and sampled larger lymph node sizes (p < 0.001). Each 1 mm increase in lymph node size raised the likelihood of diagnostic results by 1.04 times (adjOR = 1.04, 95% CI = 1.02–1.08, p = 0.002). The largest lymph node size significantly predicted diagnostic results (AUROC = 0.611, p < 0.001). A cut-off of 19.55 mm had 67.0% sensitivity and 52.2% specificity. Conclusions: Sampled larger lymph nodes increase diagnostic yield in EBUS-TBNA, reducing the need for repeat procedures and enabling earlier treatment, thereby decreasing morbidity and mortality.
- Open Access
Comparison of Mediastinal Metastases of Primary Lung Cancer Versus Extrathoracic Malignancies in Patients Obtained with Endobronchial Ultrasonography-Guided Transbronchial Needle Aspiration Biopsy: A Single-Center Retrospective Study
Background and Objectives: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive technique widely used for mediastinal staging and diagnosis in patients with lung cancer and extrathoracic malignancies. This study aimed to evaluate patient and procedural factors associated with malignant histopathological outcomes in individuals undergoing EBUS-TBNA for intrathoracic lymphadenopathy across three malignancy groups: primary lung cancer, extrathoracic solid organ malignancy, and hematological malignancy. Materials and Methods: This retrospective descriptive study included patients who underwent EBUS-TBNA at Ankara Bilkent City Hospital between March 2019 and December 2023. Demographic characteristics, histopathological findings, procedural details, additional sampling techniques, and imaging parameters, including FDG SUVmax values from pre-procedural PET-CT, were recorded. Histopathological outcomes were categorized as malignant or non-malignant. Binary and multinomial logistic regression analyses were performed to identify independent predictors of malignancy and to differentiate between malignancy groups and lung cancer subtypes. Results: A total of 776 patients underwent EBUS-TBNA, and 667 were included after excluding non-diagnostic samples. Malignancy was detected in 274 patients, including primary lung cancer (n = 213, 77.7%), extrathoracic malignancy (n = 43, 15.7%), and hematological malignancy (n = 18, 6.6%). Of the included patients, 426 (63.9%) were male; the median age was 63 (IQR = 16) years. Older age (OR = 1.03, 95% CI = 1.02–1.05, p < 0.001), male sex (OR = 2.05, 95% CI = 1.43–2.93, p < 0.001), and larger lymph node size (OR = 1.09, 95% CI = 1.06–1.11, p < 0.001) were independently associated with malignant outcomes. Younger age, female sex, and smaller lymph node size were associated with extrathoracic malignancy compared to primary lung cancer, while younger age was the only predictor of hematological malignancy. Larger lymph node size was inversely associated with adenocarcinoma and squamous cell carcinoma compared with small cell lung cancer. Conclusions: Older age, male sex, and larger lymph node size independently predict malignant EBUS-TBNA outcomes. Younger age and female sex favor extrathoracic malignancy, whereas small cell lung cancer is associated with more extensive nodal involvement. Additional bronchoscopic techniques may enhance diagnostic accuracy in selected patients.
Open AccessComparison of Mediastinal Metastases of Primary Lung Cancer Versus Extrathoracic Malignancies in Patients Obtained with Endobronchial Ultrasonography-Guided Transbronchial Needle Aspiration Biopsy: A Single-Center Retrospective Study
Background and Objectives: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive technique widely used for mediastinal staging and diagnosis in patients with lung cancer and extrathoracic malignancies. This study aimed to evaluate patient and procedural factors associated with malignant histopathological outcomes in individuals undergoing EBUS-TBNA for intrathoracic lymphadenopathy across three malignancy groups: primary lung cancer, extrathoracic solid organ malignancy, and hematological malignancy. Materials and Methods: This retrospective descriptive study included patients who underwent EBUS-TBNA at Ankara Bilkent City Hospital between March 2019 and December 2023. Demographic characteristics, histopathological findings, procedural details, additional sampling techniques, and imaging parameters, including FDG SUVmax values from pre-procedural PET-CT, were recorded. Histopathological outcomes were categorized as malignant or non-malignant. Binary and multinomial logistic regression analyses were performed to identify independent predictors of malignancy and to differentiate between malignancy groups and lung cancer subtypes. Results: A total of 776 patients underwent EBUS-TBNA, and 667 were included after excluding non-diagnostic samples. Malignancy was detected in 274 patients, including primary lung cancer (n = 213, 77.7%), extrathoracic malignancy (n = 43, 15.7%), and hematological malignancy (n = 18, 6.6%). Of the included patients, 426 (63.9%) were male; the median age was 63 (IQR = 16) years. Older age (OR = 1.03, 95% CI = 1.02–1.05, p < 0.001), male sex (OR = 2.05, 95% CI = 1.43–2.93, p < 0.001), and larger lymph node size (OR = 1.09, 95% CI = 1.06–1.11, p < 0.001) were independently associated with malignant outcomes. Younger age, female sex, and smaller lymph node size were associated with extrathoracic malignancy compared to primary lung cancer, while younger age was the only predictor of hematological malignancy. Larger lymph node size was inversely associated with adenocarcinoma and squamous cell carcinoma compared with small cell lung cancer. Conclusions: Older age, male sex, and larger lymph node size independently predict malignant EBUS-TBNA outcomes. Younger age and female sex favor extrathoracic malignancy, whereas small cell lung cancer is associated with more extensive nodal involvement. Additional bronchoscopic techniques may enhance diagnostic accuracy in selected patients.
- Open Access
- 10 September 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (3) , 219-228
Is using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality?
It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia. The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed. In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p < 0.05). In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.
- 10 September 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (3) , 219-228
Open AccessIs using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality?
It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia. The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed. In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p < 0.05). In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.
- Open Access
- 1 September 2023
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 65 (4) , 617-623
Can systolic pulmonary artery pressure be used as one of the criteria of risk stratification in acute pulmonary embolism?
Kontext: P?i akutn? plicn? embolii (PE) hraj? v?znamnou roli rychl? stanoven? diagn?zy a napl?nov?n? l??by podle klasifikace rizika ?mrt?. C?le: Posoudit p??nos znalosti hodnot systolick?ho tlaku v plicnici (systolic pulmonary artery pressure,...
- 1 September 2023
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 65 (4) , 617-623
Open AccessCan systolic pulmonary artery pressure be used as one of the criteria of risk stratification in acute pulmonary embolism?
Kontext: P?i akutn? plicn? embolii (PE) hraj? v?znamnou roli rychl? stanoven? diagn?zy a napl?nov?n? l??by podle klasifikace rizika ?mrt?. C?le: Posoudit p??nos znalosti hodnot systolick?ho tlaku v plicnici (systolic pulmonary artery pressure,...
- Open Access
- 30 June 2023
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 6 (2) , 179-183
Evaluation of Upper Extremity Venous Thrombosis with Doppler Ultrasonography in Peripheral Venous Line Applied Patients
Objectives: Peripherally inserted venous lines (PVL) may increase the risk of venous thrombosis due to vessel wall disarrangement. Aim of this study is to identify the cases of upper extremity venous thrombosis (UEVT) related to PVL since most of the PVLs applied to upper extremities. Methods: Sixty-nine hospitalized patients with previous or present PVL insertions were included in this prospective study. Upper extremity Doppler compression ultrasonography (USG) examination were performed to on all patients. The cases with detected UEVTs were evaluated as group 1 and the remaining cases were evaluated as group 2. Demographic parameters, PVL applications, intravenous treatments were compared between the groups. Results: UEVT was diagnosed by Doppler USG in 26 (37.7%) patients out of 69 patients. Lower extremity thrombosis was found in 10 (14.49%) patients. UEVT was observed in cephalic vein in 14 (53.8%) and in basilic vein in four (15.4%) out of 26 (37.7%) patients. Axillary and brachial deep UEVT was located in two (2.9%) cases. Superficial UEVT was found in 24 (34.8%) cases. Ceftriaxone, cefoperazone/sulbactam and esomeprazole were the mostly associated treatments with UEVT. UEVT was detected in five patients with PVL that were inserted only for drawing blood. Conclusion: PVL is a risk factor for UEVT since almost 1/3 of the patients revealed UEVT. When PVL is no longer needed or the need for intravenous therapy decreases, oral therapy should be planned and PVL should be removed. Removal of PVL appears to be necessary to avoid UEVT.
- 30 June 2023
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 6 (2) , 179-183
Open AccessEvaluation of Upper Extremity Venous Thrombosis with Doppler Ultrasonography in Peripheral Venous Line Applied Patients
Objectives: Peripherally inserted venous lines (PVL) may increase the risk of venous thrombosis due to vessel wall disarrangement. Aim of this study is to identify the cases of upper extremity venous thrombosis (UEVT) related to PVL since most of the PVLs applied to upper extremities. Methods: Sixty-nine hospitalized patients with previous or present PVL insertions were included in this prospective study. Upper extremity Doppler compression ultrasonography (USG) examination were performed to on all patients. The cases with detected UEVTs were evaluated as group 1 and the remaining cases were evaluated as group 2. Demographic parameters, PVL applications, intravenous treatments were compared between the groups. Results: UEVT was diagnosed by Doppler USG in 26 (37.7%) patients out of 69 patients. Lower extremity thrombosis was found in 10 (14.49%) patients. UEVT was observed in cephalic vein in 14 (53.8%) and in basilic vein in four (15.4%) out of 26 (37.7%) patients. Axillary and brachial deep UEVT was located in two (2.9%) cases. Superficial UEVT was found in 24 (34.8%) cases. Ceftriaxone, cefoperazone/sulbactam and esomeprazole were the mostly associated treatments with UEVT. UEVT was detected in five patients with PVL that were inserted only for drawing blood. Conclusion: PVL is a risk factor for UEVT since almost 1/3 of the patients revealed UEVT. When PVL is no longer needed or the need for intravenous therapy decreases, oral therapy should be planned and PVL should be removed. Removal of PVL appears to be necessary to avoid UEVT.
- Open Access
- 11 December 2021
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 15 (1) , 65-67
Response to the letter to the editor
- 11 December 2021
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 15 (1) , 65-67
Open AccessResponse to the letter to the editor
- Open Access
- 1 March 2021
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 14 (3) , 365-370
Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
- 1 March 2021
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 14 (3) , 365-370
Open AccessComparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
- 1 January 2021
- Published by Kare Publishing in Journal of İzmir Chest Hospital
- Vol. 35 (1) , 22-31
The Effect of Tobacco Addiction on Severity of COVID-19
- 1 January 2021
- Published by Kare Publishing in Journal of İzmir Chest Hospital
- Vol. 35 (1) , 22-31
The Effect of Tobacco Addiction on Severity of COVID-19
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 1863
Comparision of side effects between thrombolytic and anticoagulation therapy in patients with Pulmonary Embolism
Purpose: The treatment of Pulmonary Embolism (PE) which is life threatening disease must be planned considering risk – benefit relationship. In this study, patients with PE given thrombolytic therapy, low-molecular-weight heparin and warfarin were monitored for 5 years to compare them in terms of hemorrhage side effect due to therapy. Method: A total of 219 patients were included in the study. 50.2% (n=109) of the patient’s were female and 49.8% (n=110) were male, (p=0.20). Clinical findings, radiologic and laboratory parameters were recorded retrospectively. A total of 121 (55.25%) patients were given thrombolytic therapy (Group 1 n=121). Enoxaparin therapy was given to 205 patients (Group 2). During therapy maintenance, warfarin therapy conducted for 159 patients (Group 3). Results: Cerebral hemorrhage observed in 1 case (0.83%) in group 1, 2 case (0.98%) in group 2 and 1 case (0.62%) in group 3 (p>0.05). Gastrointestinal system (GI) bleeding happened 2 cases (1.65%) in group 1 and 2 cases (0.98%) in group 2 (p>0.05). Minor bleeding was observed at similar rates due to the treatments. There was no fatality due to hemorrhage. There is no significant difference in terms of death, recurrence, residuel chronic thrombus and chronic PE in the follow up for five years between rt-PA group (group1) and non rt-PA group (p>0.05). Conclusion: According to our results; major hemorrhage observed similar in thrombolytic, enoxaparin and warfarin therapy. Study results about the rate of cerebral hemorrhage related to thrombolytic therapy was low in contrast to the results reported in some literature before.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 1863
Comparision of side effects between thrombolytic and anticoagulation therapy in patients with Pulmonary Embolism
Purpose: The treatment of Pulmonary Embolism (PE) which is life threatening disease must be planned considering risk – benefit relationship. In this study, patients with PE given thrombolytic therapy, low-molecular-weight heparin and warfarin were monitored for 5 years to compare them in terms of hemorrhage side effect due to therapy. Method: A total of 219 patients were included in the study. 50.2% (n=109) of the patient’s were female and 49.8% (n=110) were male, (p=0.20). Clinical findings, radiologic and laboratory parameters were recorded retrospectively. A total of 121 (55.25%) patients were given thrombolytic therapy (Group 1 n=121). Enoxaparin therapy was given to 205 patients (Group 2). During therapy maintenance, warfarin therapy conducted for 159 patients (Group 3). Results: Cerebral hemorrhage observed in 1 case (0.83%) in group 1, 2 case (0.98%) in group 2 and 1 case (0.62%) in group 3 (p>0.05). Gastrointestinal system (GI) bleeding happened 2 cases (1.65%) in group 1 and 2 cases (0.98%) in group 2 (p>0.05). Minor bleeding was observed at similar rates due to the treatments. There was no fatality due to hemorrhage. There is no significant difference in terms of death, recurrence, residuel chronic thrombus and chronic PE in the follow up for five years between rt-PA group (group1) and non rt-PA group (p>0.05). Conclusion: According to our results; major hemorrhage observed similar in thrombolytic, enoxaparin and warfarin therapy. Study results about the rate of cerebral hemorrhage related to thrombolytic therapy was low in contrast to the results reported in some literature before.